Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients

S Petrovski; CEI Szoeke; NC Jones; MR Salzberg; LJ Sheffield; RM Huggins; TJ O'Brien

Journal article

Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients

S Petrovski, CEI Szoeke, NC Jones, MR Salzberg, LJ Sheffield, RM Huggins, TJ O'Brien

Neurology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2010

DOI: 10.1212/WNL.0b013e3181f25b16

Abstract

Objectives: To test the hypothesis that neuropsychiatric symptomatology is predictive of the success of seizure control in patients newly treated with antiepileptic drugs (AEDs), and that this predictive value adds to that provided by other clinical, imaging, and genomic factors in a multivariate model. Methods: One hundred seventy newly treated patients with epilepsy completed the A-B Neuropsychological Assessment Scale (ABNAS) before commencing AED therapy and were prospectively followed up for 12 months. Patients were classified as nonresponsive if they had at least 1 seizure not explained by medication noncompliance or other significant provoking factors. Results: Of the 138 patients in ..

View full abstract

University of Melbourne Researchers

Slave Petrovski Author

Cassandra Szoeke Author

Nigel Jones Author

Michael Salzberg Author

Related Projects (2)

Stress and epilepsy

High rates of anxiety and depression occur in individuals with temporal lobe epilepsy (TLE), the most common form of focal epilepsy in adult..

The Effect of Stress and Hypercortisolaemia on Limbic Epileptogenesis & Affective Disorder.

This project has the potential to provide novel insights about the causal connections between stress, psychiatric illness (specifically anxi..

Grants

Awarded by NHMRC

Funding Acknowledgements

Mr. Petrovski reports no disclosures. Dr. Szoeke has received speaker honoraria from Pfizer Inc, Lundbeck Inc., and Mayne Pharma; serves as a consultant for the Commonwealth Science and Industry Research Organisation; and receives research support from the Australian NHMRC, the National Ageing Research Institute (Melbourne Health), the Epilepsy Society of Australia, the Royal Australasian College of Physicians, the Alzheimer's Association of Australia, and the Scobie and Claire Mc Kinnon Foundation. Dr. Jones reports no disclosures. Dr. Salzberg receives research support from the Australian NHMRC and beyondblue (Australian National Depression Initiative). Dr. Sheffield has filed a patent re: A Diagnostic Assay. Dr. Huggins has received research support from the Australian NHMRC. Prof. O'Brien serves on the editorial boards of Epilepsia, the Journal of Clinical Neuroscience, and Epilepsy and Behavior; has received speaker honoraria from Janssen and sanofi-aventis 2009; and receives research support from UCB, Abbott Laboratories, Janssen, the Australian NHMRC, the Epilepsy Research Foundation, NARSAD, and the Royal Melbourne Hospital Neuroscience Foundation.Supported by the NHMRC (400088 and 566843 to T.J.O., M.S.,and N.J.), RMH Home Lottery Research Fund of Melbourne Health (chief investigator S. P.), Pfizer Inc and the Victor Hurley (chief investigator C. S.), and the Royal Melbourne Hospital Neuroscience Research Foundation (chief investigator T.J.O.). BioGrid Australia (formerly Bio21: MMIM) provided server space to house the databases, implemented an interface to facilitate data entry, and funded support staff to enter the data.